LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….
UTRECHT, The Netherlands and PHILADELPHIA , Aug. 14, 2023 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V….
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent….
Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent….
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A…
Company received Complete Response Letter from FDA for avasopasem and intends to request Type A…
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023…
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023…
Financing led by RA Capital Management with participation from new and existing investors Expected net…
Financing led by RA Capital Management with participation from new and existing investors Expected net…
For the three months ended June 30, 2023: Revenues of $793.0 million GAAP net income…
For the three months ended June 30, 2023: Revenues of $793.0 million GAAP net income…
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and…
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and…
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy;…
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy;…
– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line…
– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line…
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase…
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase…